These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 20022534)
1. Socioeconomic impact of ankylosing spondylitis in Tunisia. Younes M; Jalled A; Aydi Z; Zrour S; Korbaa W; Ben Salah Z; Letaief M; Bejia I; Touzi M; Bergaoui N Joint Bone Spine; 2010 Jan; 77(1):41-6. PubMed ID: 20022534 [TBL] [Abstract][Full Text] [Related]
2. Costs and work limitation of patients with ankylosing spondylitis in China. Tu L; Rai JC; Cao S; Lin Z; Hu Z; Gu J Clin Exp Rheumatol; 2014; 32(5):661-6. PubMed ID: 25234798 [TBL] [Abstract][Full Text] [Related]
3. Costs and quality of life of patients with ankylosing spondylitis in Canada. Kobelt G; Andlin-Sobocki P; Maksymowych WP J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660 [TBL] [Abstract][Full Text] [Related]
4. Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Krüger K; von Hinüber U; Meier F; Tian H; Böhm K; Jugl SM; Borchert K; Meise D; König C; Braun S Rheumatol Int; 2018 Nov; 38(11):2121-2131. PubMed ID: 30094685 [TBL] [Abstract][Full Text] [Related]
5. The burden of ankylosing spondylitis in Spain. Kobelt G; Sobocki P; Mulero J; Gratacos J; Pocovi A; Collantes-Estevez E Value Health; 2008; 11(3):408-15. PubMed ID: 18489666 [TBL] [Abstract][Full Text] [Related]
6. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis. Sağ S; Nas K; Sağ MS; Tekeoğlu İ; Kamanlı A J Back Musculoskelet Rehabil; 2018; 31(3):499-505. PubMed ID: 29504521 [TBL] [Abstract][Full Text] [Related]
7. A systematic literature review of the economic impact of ankylosing spondylitis. Palla I; Trieste L; Tani C; Talarico R; Cortesi PA; Mosca M; Turchetti G Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S136-41. PubMed ID: 23072824 [TBL] [Abstract][Full Text] [Related]
9. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514 [TBL] [Abstract][Full Text] [Related]
10. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Zhu TY; Tam LS; Lee VW; Hwang WW; Li TK; Lee KK; Li EK Rheumatology (Oxford); 2008 Sep; 47(9):1422-5. PubMed ID: 18635597 [TBL] [Abstract][Full Text] [Related]
11. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Boonen A; van der Heijde D; Landewé R; Spoorenberg A; Schouten H; Rutten-van Mölken M; Guillemin F; Dougados M; Mielants H; de Vlam K; van der Tempel H; van der Linden S Ann Rheum Dis; 2002 May; 61(5):429-37. PubMed ID: 11959767 [TBL] [Abstract][Full Text] [Related]
12. Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey. Akkoç N; Direskeneli H; Erdem H; Gül A; Kabasakal Y; Kiraz S; Balkan Tezer D; Hacıbedel B; Hamuryudan V Rheumatol Int; 2015 Sep; 35(9):1473-8. PubMed ID: 25749712 [TBL] [Abstract][Full Text] [Related]
13. Impact of the ankylosing spondylitis on the professional activity. Montacer Kchir M; Mehdi Ghannouchi M; Hamdi W; Azzouz D; Kochbati S; Saadellaoui K; Daoud L; Hamida AB; Zouari MB Joint Bone Spine; 2009 Jul; 76(4):378-82. PubMed ID: 19525138 [TBL] [Abstract][Full Text] [Related]
14. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Boonen A; Brinkhuizen T; Landewé R; van der Heijde D; Severens JL Ann Rheum Dis; 2010 Jun; 69(6):1123-8. PubMed ID: 20439293 [TBL] [Abstract][Full Text] [Related]
15. Resource utilisation and cost of ankylosing spondylitis in Brazil. Torres TM; Ferraz MB; Ciconelli RM Clin Exp Rheumatol; 2010; 28(4):490-7. PubMed ID: 20810034 [TBL] [Abstract][Full Text] [Related]
16. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Boonen A; van der Heijde D; Landewé R; Guillemin F; Rutten-van Mölken M; Dougados M; Mielants H; de Vlam K; van der Tempel H; Boesen S; Spoorenberg A; Schouten H; van der Linden S Ann Rheum Dis; 2003 Aug; 62(8):732-40. PubMed ID: 12860728 [TBL] [Abstract][Full Text] [Related]
17. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Franke LC; Ament AJ; van de Laar MA; Boonen A; Severens JL Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S118-23. PubMed ID: 19822057 [TBL] [Abstract][Full Text] [Related]
18. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Kvamme MK; Lie E; Kvien TK; Kristiansen IS Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479 [TBL] [Abstract][Full Text] [Related]
19. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A; Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552 [TBL] [Abstract][Full Text] [Related]
20. Healthcare costs and productivity losses directly attributable to ankylosing spondylitis. Rafia R; Ara R; Packham J; Haywood KL; Healey E Clin Exp Rheumatol; 2012; 30(2):246-53. PubMed ID: 22409861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]